Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Deanol Aceglumate→

Deanol Aceglumate Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
3342-61-8
Molecular formula
C11H22N2O6
Molecular weight
278.3 g/mol
Drug class
CNS stimulant and cholinergic precursor saltdeanol–N-acetyl-L-glutamate
Mechanism of action
A salt of deanol (2-dimethylaminoethanol) and N-acetyl-L-glutamate. Deanol is a choline-related precursor that has been proposed to influence acetylcholine availability and central cholinergic signalling; the pharmacological contribution of the aceglumate countercomponent and clinical mechanism are not well established.
Indications / reported uses
  • Marketed in some countries for cognitive symptoms or neurological complaints, but clinical efficacy evidence and authorised indications are limited and jurisdiction-specific. It should not be presented as an established treatment for dementia or other neurodegenerative disease.

Sources: https://precision.fda.gov/ginas/app/ui/substances/5fc41def-20e2-46ce-86d8-406a806a1691 · https://pubchem.ncbi.nlm.nih.gov/compound/71125 · https://www.ebi.ac.uk/chembl/explore/compound/CHEMBL3833347 · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Deanol Aceglumate Environmental Risk Assessment (ERA) (the Deanol Aceglumate ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.